Human B-cell and Progenitor Stages As Determined by Probability State Modeling of Multidimensional Cytometry Data

Overview

Journal Cytometry B Clin Cytom

Specialty Cell Biology

Date 2015 Apr 9

PMID 25850810

Citations 7

Authors

C Bruce Bagwell

Beth L Hill

Brent L Wood

Paul K Wallace

Muaz Alrazzak

Abigail S Kelliher

Frederic I Preffer

Affiliations

Soon will be listed here.

Abstract

Background: Human progenitor and B-cell development is a highly regulated process characterized by the ordered differential expression of numerous cell-surface and intracytoplasmic antigens. This study investigates the underlying coordination of these modulations by examining a series of normal bone marrow samples with the method of probability state modeling or PSM.

Results: The study is divided into two sections. The first section examines B-cell stages subsequent to CD19 up-regulation. The second section assesses an earlier differentiation stage before and including CD19 up-regulation. POST-CD19 ANTIGENIC UP-REGULATION: Statistical analyses of cytometry data derived from sixteen normal bone marrow specimens revealed that B cells have at least three distinct coordinated changes, forming four stages labeled as B1, B2, B3, and B4. At the end of B1; CD34 antigen expression down-regulates with TdT while CD45, CD81, and CD20 slightly up-regulate. At the end of B2, CD45 and CD20 up-regulate. At the end of B3 and beginning of B4; CD10, CD38, and CD81 down-regulate while CD22 and CD44 up-regulate. PRE-CD19 ANTIGENIC UP-REGULATION: Statistical analysis of ten normal bone marrows revealed that there are at least two measurable coordinated changes with progenitors, forming three stages labeled as P1, P2, and P3. At the end of P1, CD38 up-regulates. At the end of P2; CD19, CD10, CD81, CD22, and CD9 up-regulate while CD44 down-regulates slightly.

Conclusions: These objective results yield a clearer immunophenotypic picture of the underlying cellular mechanisms that are operating in these important developmental processes. Also, unambiguously determined stages define what is meant by "normal" B-cell development and may serve as a preliminary step for the development of highly sensitive minimum residual disease detection systems. A companion article is simultaneously being published in Cytometry Part A that will explain in further detail the theory behind PSM. Three short relevant videos are available in the online supporting information for both of these papers.

Citing Articles

Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China.

Leung K, Cai J, Liu Y, Chan K, Shao J, Yang H Leukemia. 2023; 38(2):250-257.

PMID: 38001171 PMC: 10844073. DOI: 10.1038/s41375-023-02089-3.

Pax5 mediates the transcriptional activation of the CD81 gene.

Hosokawa K, Ishimaru H, Watanabe T, Fujimuro M Sci Rep. 2021; 11(1):22919.

PMID: 34824296 PMC: 8616915. DOI: 10.1038/s41598-021-02082-9.

Full-Length Transcriptome: A Reliable Alternative for Single-Cell RNA-Seq Analysis in the Spleen of Teleost Without Reference Genome.

Huang L, Qiao Y, Xu W, Gong L, He R, Qi W Front Immunol. 2021; 12:737332.

PMID: 34646272 PMC: 8502891. DOI: 10.3389/fimmu.2021.737332.

Minimal residual disease assessment in acute lymphoblastic leukemia by 4-color flow cytometry: Recommendations from the MRD Working Group of the Brazilian Society of Bone Marrow Transplantation.

Ikoma-Colturato M, Beltrame M, Furtado F, Pimenta G, da Costa E, Azambuja A Hematol Transfus Cell Ther. 2020; 43(3):332-340.

PMID: 33281111 PMC: 8446261. DOI: 10.1016/j.htct.2020.09.148.

Dynamics of B Cell Recovery In Kidney/Bone Marrow Transplant Recipients.

Gao B, Gu Y, Rong C, Moore C, Porcheray F, Wong W Transplantation. 2017; 101(11):2722-2730.

PMID: 28422925 PMC: 5648631. DOI: 10.1097/TP.0000000000001789.

References

Borowitz M, Devidas M, Hunger S, Bowman W, Carroll A, Carroll W . Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008; 111(12):5477-85. PMC: 2424148. DOI: 10.1182/blood-2008-01-132837. View

Matthias P, Rolink A . Transcriptional networks in developing and mature B cells. Nat Rev Immunol. 2005; 5(6):497-508. DOI: 10.1038/nri1633. View

Jackson S, Wilson P, James J, Capra J . Human B cell subsets. Adv Immunol. 2008; 98:151-224. DOI: 10.1016/S0065-2776(08)00405-7. View

Rawlings D, Quan S, Hao Q, Thiemann F, Smogorzewska M, Witte O . Differentiation of human CD34+CD38- cord blood stem cells into B cell progenitors in vitro. Exp Hematol. 1997; 25(1):66-72. View

Krause D, Scadden D, Preffer F . The hematopoietic stem cell niche--home for friend and foe?. Cytometry B Clin Cytom. 2013; 84(1):7-20. PMC: 3691061. DOI: 10.1002/cyto.b.21066. View

Herbert D, Miller D, Bagwell C . Automated analysis of flow cytometric data for CD34+ stem cell enumeration using a probability state model. Cytometry B Clin Cytom. 2012; 82(5):313-8. DOI: 10.1002/cyto.b.21032. View

Qiu P, Simonds E, Bendall S, Gibbs Jr K, Bruggner R, Linderman M . Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat Biotechnol. 2011; 29(10):886-91. PMC: 3196363. DOI: 10.1038/nbt.1991. View

LeBien T . Fates of human B-cell precursors. Blood. 2000; 96(1):9-23. View

Cannizzo E, Carulli G, Del Vecchio L, Ottaviano V, Bellio E, Zenari E . The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model. Am J Clin Pathol. 2012; 137(3):377-86. DOI: 10.1309/AJCP63TOCFNAMDMS. View

10.

Bagwell C, Hunsberger B, Herbert D, Munson M, Hill B, Bray C . Probability state modeling theory. Cytometry A. 2015; 87(7):646-60. DOI: 10.1002/cyto.a.22687. View

11.

Gathings W, Lawton A, Cooper M . Immunofluorescent studies of the development of pre-B cells, B lymphocytes and immunoglobulin isotype diversity in humans. Eur J Immunol. 1977; 7(11):804-10. DOI: 10.1002/eji.1830071112. View

12.

LeBien T, Wormann B, Villablanca J, LAW C, Steinberg L, Shah V . Multiparameter flow cytometric analysis of human fetal bone marrow B cells. Leukemia. 1990; 4(5):354-8. View

13.

Bagwell C . Breaking the dimensionality barrier. Methods Mol Biol. 2010; 699:31-51. DOI: 10.1007/978-1-61737-950-5_2. View

14.

Sanz E, Munoz-A N, Monserrat J, Van-Den-Rym A, Escoll P, Ranz I . Ordering human CD34+CD10-CD19+ pre/pro-B-cell and CD19- common lymphoid progenitor stages in two pro-B-cell development pathways. Proc Natl Acad Sci U S A. 2010; 107(13):5925-30. PMC: 2851857. DOI: 10.1073/pnas.0907942107. View

15.

Sedek L, Bulsa J, Sonsala A, Twardoch M, Wieczorek M, Malinowska I . The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts?. Cytometry B Clin Cytom. 2014; 86(5):329-39. DOI: 10.1002/cyto.b.21176. View

16.

Lee J, Spidlen J, Boyce K, Cai J, Crosbie N, Dalphin M . MIFlowCyt: the minimum information about a Flow Cytometry Experiment. Cytometry A. 2008; 73(10):926-30. PMC: 2773297. DOI: 10.1002/cyto.a.20623. View

17.

Bendall S, Davis K, Amir E, Tadmor M, Simonds E, Chen T . Single-cell trajectory detection uncovers progression and regulatory coordination in human B cell development. Cell. 2014; 157(3):714-25. PMC: 4045247. DOI: 10.1016/j.cell.2014.04.005. View

18.

Pieper K, Grimbacher B, Eibel H . B-cell biology and development. J Allergy Clin Immunol. 2013; 131(4):959-71. DOI: 10.1016/j.jaci.2013.01.046. View

19.

Warnatz K, Schlesier M . Flowcytometric phenotyping of common variable immunodeficiency. Cytometry B Clin Cytom. 2008; 74(5):261-71. DOI: 10.1002/cyto.b.20432. View

20.

Miller D, Hunsberger B, Bagwell C . Automated analysis of GPI-deficient leukocyte flow cytometric data using GemStone™. Cytometry B Clin Cytom. 2012; 82(5):319-24. DOI: 10.1002/cyto.b.21024. View